Sobi Acquires Novimmune’s Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology

Sobi Acquires Novimmune’s Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology

Shots:

  • Novimmune to receive $115.86M, out of $518.76M and has already received $402.9M under its exclusive license agreement signed with Sobi in 2018. Sobi to get IP & patent rights, associated employees of emapalumab with an option for shared financial rights to NI-1701 & NI-1801.
  • Sobi has also received the US FDA’s PR voucher for emapalumab with an expected completion of the acquisition in Q3’19 and plans to establish a center of excellence in Sweden and Switzerland for hematology & immunology respectively
  • Emapalumab is a mAb, binding to & neutralizing interferon gamma (IFNγ), indicated for HLH in pediatric & adults. In Jul’18, Novimmune grants exclusive global rights of emapalumab to Sobi which is now replaced with the acquisition

 Click here, Click here to read full press release/ article | Ref: Sobi | Image:Laboratory focus